News

ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024

LAUSANNE, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in…

1 year ago

Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs

Breakthrough Device Designations are granted by the U.S. FDA to expedite review of promising technologies that address high unmet needs…

1 year ago

Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2024

WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced…

1 year ago

InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th

-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, and MIAMI, July 30, 2024 (GLOBE…

1 year ago

Day One Announces Oversubscribed $175.0 Million Private Placement

BRISBANE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a…

1 year ago

Foresight Diagnostics Expands Series B Financing to $73.75 Million to Advance the Foresight CLARITY™ MRD Platform

BOULDER, Colo., July 30, 2024 (GLOBE NEWSWIRE) -- Foresight Diagnostics, Inc. (“Foresight”), a leading diagnostics company specializing in the development…

1 year ago

Voyager Therapeutics Announces Second Quarter 2024 Conference Call and Webcast

LEXINGTON, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic…

1 year ago

Amicus Therapeutics to Announce Second Quarter 2024 Financial Results on August 8, 2024

PRINCETON, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a…

1 year ago

Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update

– Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally…

1 year ago

BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024

NEW HAVEN, Conn., July 30, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence…

1 year ago